Kornimate/medical-research-clean huggingface dataset:
the effect of essential oil inhalation patches on perceived burn-out & stress on an inpatient medical-surgery unit.

Conditions: Nursing Personnel

Summary: the purpose of this clinical study is to compare the use of an essential oil inhalation patch in medical surgical nurses on perceived burn-out and stress. the main question is can essential oil inhalation patches decrease perceived burn-out and stress. participants will * take part in the study over 30 days, alternating weeks, resulting in each participant using six patches over six shifts. * complete anonymous perceived stress survey (pss) before the study begins and at the conclusion of the study. * participants will also complete a (different) survey after two weeks.

essential oil inhalation patches are a nonpharmacological option that is worn by the nursing staff on an inpatient medical-surgical unit to determine the efficacy of patch on staff perceived stress \& burn-out levels. each participant will wear a new patch during six work shifts. location is on chest or the id badge area where it can be easily accessed to. the patch provides up to 8 hours of aromatic support. the patches use a unique patented technology that slows the release of the aromatic molecules while maintaining the purity and vitality of the essential oil. the fda approved medical adhesive patches are roughly 1x1" in size, and are inhalation only- no contact of essential oils on skin. the patch is portable and discreet. no overwhelming aroma for others. the patch has directions for use on package with an expiration date. used for a non-specific purpose for stress reduction environment for this study.

Eligibility criteria:
inclusion criteria: * full time employee (nurse, lpn, or lna) working on l3wd and l4wc * at least 18 years of age exclusion criteria: * pregnant/breastfeeding or planning to become pregnant

Keywords: essential oil inhalation patches essential oil and nursing stress medical-surgical unit
labor induction and pain relief with paracetamol versus placebo

Conditions: Labor Pain

Summary: single-blind study conducted on 2 randomly selected groups of pregnant women carrying a single fetus (from week 37 onward). one group will receive paracetamol 1 gr i.v. prior to insertion of balloon catheter and the control group will receive 100 ml sodium chloride 0.9% i.v prior to insertion of balloon catheter. an assessment of pain management will be conducted using various assessment tools. additionally, mode of delivery and time from catheter insertion to delivery will be assessed.

single-blind study conducted on 2 randomly selected groups of pregnant women carrying a single fetus (from week 37 onward). one group will receive paracetamol 1 gr i.v. prior to insertion of balloon catheter and the control group will receive 100 ml sodium chloride 0.9% i.v prior to insertion of balloon catheter. assessment of pain during catheter balloon insertion will be assessed using visual analogue scale (vas) instrument with scores 1 to 10. an assessment of pain management will also be conducted using various assessment tools: 1. brief pain inventory short form (bpisf) - before balloon insertion and at various time intervals. 2. hospital anxiety and depression scale (hads) - 1 hr. before balloon insertion and immediately upon removal of catheter. 3. patient experience questionnaire - upon transfer to delivery room. 4. socio-demographic questionnaire additionally, obstetrics outcomes will be recorded including time from catheter to delivery, mode of delivery. these parameters will be compared between the two groups (those who recieved paracetamol versus normal saline 0.9%).

Eligibility criteria:
inclusion criteria: women from 18-44 yrs of age 37 weeks pregnant and onward singleton pregnancy induction of labor using a balloon catheter nulliparity exclusion criteria: 1. sensitivity to paracetamol. 2. past cesarean section 3. multiple pregnancy
evaluating the impact of the intervention of a pharmacist in the operating room on the appropriate use of sterile medical devices

Conditions: Surgery

Summary: assess the impact of the intervention of a clinical pharmacist expert in sterile medical devices


Eligibility criteria:
inclusion criteria: * - the patient must be a member or beneficiary of a health insurance plan. * the patient is managed for scheduled surgery (full hospitalization or outpatient) in the udg (urology digestive gynecology) operating room. exclusion criteria: * - the subject is in a period of exclusion determined by a previous study. * the subject is under judicial protection. * the subject (or his/her legal representative) has expressed his/her opposition to participate in the study. * the patient is undergoing emergency surgery in the udg (urology digestive gynecology) operating room. * it is not possible to give informed information about the subject. translated with www.deepl.com/translator (free version)
prospective measurement of post-treatment lymphedema

Conditions: Melanoma

Summary: the goal of this study is to measure the amount of limb swelling (lymphedema) that sometimes occurs after melanoma treatment, and to find out how people feel and react to the diagnosis and treatment of melanoma.

if you choose to take part in this study, you will have measurements taken of your arms or legs using a perometer and a bioimpedance machine. the perometer is a machine that painlessly measures the fluid in your limb using two-directional infrared lights. these lights are located in the frame of the machine that encircles the arm or leg during the measurement. the bioimpedance is a machine that measures the fluid in your arm or leg by passing a very small current through the body similar to an electrocardiogram (ekg). these very small currents are located in electrodes that are placed on the hands and feet during the measurement. both machines are able to pick up changes in limb size. you will also be asked to complete a set of questionnaires relating to any symptoms that you may experience in your limbs and/or trunk (chest, stomach, and hip areas) during and following your standard cancer treatment. additional questionnaires, along with your limb measurements, will be done at your regularly-scheduled follow-up clinic visits, 3-6 months, 9-12 months, 15-18 months, 21-24 months and 27- 30 months. you will complete the additional questionnaires using a laptop computer or a hardcopy. the measurements and questionnaires will take 45-60 minutes to complete each time. some of the data from this study may be sent to the university of missouri for analysis. the data that is sent will not have any personal identifiers. researchers at university of missouri will not be able to link the data to the protected health information or personal identity of any individual participant. this is an investigational study. up to 350 patients will take part in this study. all patients will be enrolled at md anderson.

Eligibility criteria:
inclusion criteria: 1. patients with a confirmed diagnosis (m.d. anderson pathology) of invasive cutaneous melanoma (stages i-iii) will be recruited for participation as they present for their initial clinical evaluation to the university of texas m.d. anderson melanoma and skin center. 2. prior to surgical treatment 3. patients who can knowledgeably and voluntarily provide an informed consent to participate. the informed consent will be signed and dated. 4. fluent in english. 5. at least 18 years of age. exclusion criteria: 1. patients with a prior history of lymphedema or melanoma prior to treatment. 2. patients who are unable to consent due to other medical illnesses or disorientation to person, place or time. 3. patients with known distant metastatic disease (stage iv). 4. patients with implanted device (pace maker), orthopedic implants, and metal frames. 5. presence of concurrent malignancy that requires active treatment, such as chemotherapy or biotherapy, prior to enrollment.

Keywords: melanoma lymphedema limb swelling questionnaire quality of life physical function survey
a clinical trial to evaluate the efficacy and safety of anotinib hydrochloride capsule combined with epirubicin hydrochloride versus placebo combined with epirubicin hydrochloride in first-line treatment of advanced soft tissue sarcoma

Conditions: Soft Tissue Sarcoma

Summary: a multicenter, randomized, double-blind, parallel-controlled phase iii trial to evaluate the efficacy and safety of anotinib hydrochloride capsule combined with epirubicin hydrochloride versus placebo combined with epirubicin hydrochloride in first-line treatment of advanced soft tissue sarcoma


Eligibility criteria:
inclusion criteria: * eastern cooperative oncology group (ecog) performance status score of 0 to 1. * life expectancy \>=3 months. * female patients of childbearing age should agree to use contraceptive measures during the study period and for at least 6 months after study is stopped; male patients should agree to use contraception during the study period and for at least 6 months after study is stopped. * understood and signed an informed consent form. exclusion criteria: * diagnosed and/or treated additional malignancy within 5 years before the first dose. * with factors affecting oral medication. * received major surgical treatment, open biopsy or obvious traumatic injury within 4 weeks before the first dose. * a history of psychotropic drug abuse or have a mental disorder. * any severe and/or uncontrolled diseas. * has received chinese patent medicines with anti-tumor indications within 2 weeks before the first dose. * has participated in other clinical studies within 4 weeks before the first dose. * according to the judgement of the investigators, there are other factors that subjects are not suitable for the study.
pre-habilitation with mindfulness and exercise for patients undergoing radical cystectomy (primer trial)

Conditions: Bladder Cancer; Non-muscle-invasive Bladder Cancer; Muscle-Invasive Bladder Carcinoma

Summary: the primer (pre-habilitation with mindfulness and exercise for patients undergoing radical cystectomy) trial is a pilot designed to estimate the feasibility of integrating a home-based pre-operative exercise and mindfulness program (pre-habilitation program) for patients scheduled to undergo radical cystectomy for bladder cancer in an attempt to improve both physical and psychological conditioning pre-operatively.


Eligibility criteria:
inclusion criteria: * provision of signed and dated informed consent form * stated willingness to comply with all study procedures and availability for the duration of the study * male or female, aged ≥18 years of age * good surgical candidate determined by treating surgeon * histologically documented muscle invasive urothelial carcinoma of the bladder, high-risk non-muscle invasive bladder cancer, non-muscle invasive bladder cancer refractory to bcg, cisplatin ineligible muscle invasive bladder cancer receiving upfront cystectomy, urothelial carcinoma of the bladder with variant histology * adequate organ function per protocol definition * ecog performance status ≤2 * received medical clearance to complete cardiopulmonary exercise testing * willing to use the personal or study provided devices for monitoring and performing the exercise routines. * fluent in english or spanish for the eortc qlq questionnaire * no known contraindications to high intensity exercise exclusion criteria: * contraindications to participating in aerobic exercise * currently participating in an aerobic exercise program * new onset chest pain nor dyspnea with exertion * histologically documented micropapillary or sarcomatoid bladder cancer * distant metastatic carcinoma

Keywords: mindfulness meditation physical exercise pre-habilitation
prospective case-series of ligasure advance pistol grip and ligasure blunt tip

Conditions: Morbid Obesity

Summary: the study is primarily to evaluate the safety and efficacy of the ligasure advance™ pistol grip and ligasure™ blunt tip using the force triad™ energy platform during roux-en-y and gastric reduction procedures (sleeve gastrectomy or placation), respectively. also, economic value of using ligasure in gastric surgeries will be appraised. in this prospective case series, 60 patients previously scheduled to undergo a roux-en-y or gastric reduction procedure (sleeve gastrectomy or placation) will have hemostasis controlled with ligasure advance ™ pistol grip or ligasure™ blunt tip, respectively. all subjects undergoing roux-en-y or gastric reduction procedures (sleeve gastrectomy or placation) procedure at durham regional hospital will be recruited. data analysis will be performed using the data collected in the software program titled metabar at duke university medical center. categorical variables will be summarized as proportions for each category; continuous measures will be summarized by mean and standard deviation or median and range as appropriated for the data distribution. procedure-related risks are those typically associated with gastric procedures and general anesthesia including intra-operative bleeding, infection, and injury to surrounding organs and structures. device related risks include those normally associated with the use of electrosurgery including intra-operative bleeding, unintended tissue burns, electrical shock, and electrical stimulation of muscles and nerves.


Eligibility criteria:
inclusion criteria: * patients 18 years of age or older * patients who will undergo a roux-en-y or gastric reduction procedures (sleeve gastrectomy or placation) * patients with a bmi between 40-60 exclusion criteria: * patients under 18 years of age * patients participating in other competing research protocol(s) * patients for whom electrosurgery is contraindicated * patients unable to tolerate general anesthesia * patients who are pregnant * patients unwilling or unable to provide informed consent * patients who have undergone significant upper gi surgery leading to adhesion formation, as determined by the principal investigator.

Keywords: gastric procedures force triad ligasure advance pistol grip ligasure blunt tip
new retinoid agent combined with arsenic trioxide for untreated acute promyelocytic leukemia

Conditions: Acute Promyelocytic Leukemia

Summary: the safety and efficacy of combining nrx 195183 with arsenic trioxide in treating untreated apl will be assessed.

the primary objectives of this study are in newly diagnosed apl patients: * to evaluate the efficacy (complete and molecular response rates) and toxicity of nrx 195183 in induction therapy * to evaluate the efficacy (molecular response rates) and toxicity of nrx 195183 in combination with arsenic trioxide (as2o3) in consolidation therapy. * to evaluate the efficacy (event free-survival, disease-free survival) and toxicity of nrx 195183 as maintenance therapy for patients with apl who achieve a molecular complete response.

Eligibility criteria:
inclusion criteria: * diagnosis patients must have a clinical diagnosis of acute promyelocytic leukemia (apl) morphology or fab m3 variant confirmed by rt-pcr assay for pml-rarα or chromosome analysis/fish showing t(15:17) translocation. a patient may be entered prior to confirmatory studies, but a patient who is subsequently found to be pml-rarα negative will be removed from protocol treatment. * prior treatment the patient must not have received any systemic definitive treatment for apl, including cytotoxic chemotherapy, retinoids or arsenic trioxide. prior therapy with corticosteroids, hydroxyurea or leukapheresis will not exclude the patient. * age: patients must be of age eighteen (18) or above. * other criteria * patients must have the following laboratory values: * bilirubin equal or less than 1.5 times the upper limit of normal. * creatinine equal or less than 1.5 times the upper limit of normal * pregnancy / nursing status * patients entered into this study should be non-pregnant and non-nursing and should not plan on becoming pregnant while on treatment. treatment under this protocol would expose an unborn child to significant risks. treatment. women and men of reproductive potential should agree to use an effective means of birth control. there is an extremely high risk of fetal malformation if pregnancy occurs while on treatment in any amount with retinoid drugs even for short periods. exclusion criteria: * non-apl, aml patients should be excluded from the study. * other serious illnesses which would limit survival to 1 year. * psychiatric conditions which would prevent compliance with treatment or informed consent. * uncontrolled or severe cardiovascular disease. this would include history of a recent acute myocardial infarction, uncontrolled congestive heart failure, or active angina. * aids or hiv positive patients, although hiv test is not required for accrual.
low-frequency repetitive nerve stimulation in myotonic dystrophy type 1

Conditions: Myotonic Dystrophy 1

Summary: the study design is a prospective cohort study. it aims to evaluate the neuromuscular junction in dystrophic myotonia 1 (dm 1) using low-frequency repetitive nerve stimulation (rns) on several nerve-muscle pairs of the one side including proximal and distal muscles of upper and lower extremities. first, it will be investigated whether a decrement with 3 hz stimulation, as described in literature, is reproducible in our patient population. if this is the case, it will be examined whether it is the consequence of a dysfunction of the neuromuscular junction or rather linked to a hypo-excitability of some muscle fibers due to myotonia. for this purpose, additional tests including short exercise test (to observe any decrement resulting from an inexcitability in myotonic muscle fibers) and needle emg (for mapping myotonic discharges in the muscles tested with repetitive nerve stimulation) will be performed. single fiber-emg will not be provided in this study as an abnormal result does not necessarily indicate a dysfunction of the neuromuscular junction but could just as well be due to the muscular dystrophy in the context of dm1. finally, it will be investigated if there is a correlation between the decrement with 3 hz stimulation and clinical signs as fixed muscle weakness (via medical research counsil (mrc) scale, dm-activ scale \[30\]) and fatigue (via mg-adl scale).


Eligibility criteria:
inclusion criteria: \* genetically confirmed dm1 exclusion criteria: * minor age * auto-immune diseases * medical conditions involving the neuromuscular junction: (myasthenia gravis, lambert-eaton myasthenic syndrome, congenital myasthenia syndromes).
inhaled iloprost for sarcoidosis-associated pulmonary hypertension

Conditions: Sarcoidosis; Pulmonary Arterial Hypertension

Summary: this trial will study the treatment of sarcoidosis-associated pulmonary arterial hypertension with inhaled iloprost, a drug approved for primary pulmonary arterial hypertension.

pulmonary hypertension has been described in sarcoidosis. it can be a significant problem, not responsive to treatment with anti-inflammatory drugs for the sarcoidosis (1;2). inhaled iloprost has been approved for treatment of pulmonary hypertension (3). we propose to study the effectiveness of inhaled iloprost for sarcoidosis associated pulmonary hypertension (sapah). this is an open label trial, with patients receiving 16 weeks of therapy. clinical and hemodynamic outcome of therapy will be assessed.

Eligibility criteria:
inclusion criteria: * patients with known sarcoidosis 17 * age 18 or greater * patients with documented pulmonary hypertension with a pa mean \> 25 mm as measured by cardiac catheterization within six months of entry into the study * patients with dyspnea * six minute walk distance of between 100 to 500 meters * patients on stable immunotherapy for their sarcoidosis, including prednisone, methotrexate, azathioprine, hydroxychloroquine, cyclophosphamide, thalidomide, and/or infliximab * patients able to provide written consent exclusion criteria: * patients on pulmonary vasodilator drugs (flolan, remodulin, bosentan, sildenafil) in the prior 28 days (patients on stable dose of calcium channel blocker for more than 1 month prior to right heart catheterization can be continued on the calcium channel blocker) * patients with severe airway obstruction as defined by fev1/fvc of less than 35% * patients with world health organization (who) class iv status * patients who are pregnant or breast feeding * patients with significant left ventricular dysfunction with a left ventricular ejection fraction of less than 35% * significant liver dysfunction not due to sarcoidosis * patients with severe other organ disease felt by investigators to impact survival during the course of the study * patients unable to perform the 6 inhalation treatments required for therapy * patients with \< 90 mm hg systolic systemic blood pressure will be excluded

Keywords: sarcoidosis dyspnea interstitial lung disease
bio electro stimulation therapy for parkinson's disease

Conditions: Parkinson Disease

Summary: parkinson's disease (pd) is a neurodegenerative disorder characterized by motor dysfunction and non-motor symptoms. here, the investigators propose in a pilot device feasibility trial to examine whether "bio electro stimulation therapy" (b.e.s.t.) with a small, non-invasive, handheld electronic device designed to apply micro current stimulation to a person's hand can ameliorate some of the symptoms of pd.

parkinson's disease (pd) is a neurodegenerative disorder characterized by motor dysfunction, cognitive impairment, and other non-motor symptoms. here, we propose to use "bio electro stimulation therapy" (b.e.s.t.) using the "e-tapper tt-r1"owned by immumax international co. ltd., a hong kong based company. the "e-tapper" is a non-invasive, handheld electronic device designed to apply micro current stimulation to a person's hand at specified points representing various body parts, such as the head, leg, or foot. this is one form of bio electro stimulation therapy, known as "11-point hand treatment system". the current delivered is less than one milliampere. anecdotal evidence suggests that this micro current stimulation may reduce resting tremor, restore facial expressions, and improve ease of movement, mood, and sleep quality in patients with pd. scientific evidence for the effectiveness of the b.e.s.t. hand therapy appears to be lacking in the english language (western) literature. the goal of this pilot device feasibility study is to examine whether b.e.s.t. can increase physical activity and functional fitness, enhance cognition, improve mood and subjective sleep quality, and modulate resting tremor and gait parameters in pd patients over a 6-week period.

Eligibility criteria:
inclusion criteria: * high functioning without presence of cognitive impairment or dementia * native-english speaker or fluent in english * diagnosis of parkinson's disease (hoehn \& yahr stages i-iii) exclusion criteria: * implanted medical devices, such as a pacemaker or defibrillator * prescription medication or other drugs that affect the brain (e.g. anti-depressants, anxiolytics), except prescription medication for the treatment of parkinson's disease * poor vision that cannot be corrected with glasses or contact lenses * presence of musculoskeletal impairments (e.g. fractures, hemiplegia, chronic joint pain) * not being able to walk without assistance * diagnosis of dementia or mild cognitive impairment * diabetes mellitus * taking medications for diabetes mellitus * skin irritation, disease or wound on the hands * current heart conditions, such as congestive heart failure, tachycardia, or other arrhythmias * history of heart attack * psychiatric or neurological disorders other than parkinson's disease (e.g. major depressive disorder, anxiety disorder, epilepsy)

Keywords: physical activity fitness cognition mood depression anxiety sleep quality tremor gait